Filing Flows › Integra Lifesciences Holdings (IART) › R&D spending
Integra Lifesciences Holdings (IART) R&D spending by quarter
Integra Lifesciences Holdings' R&D spending was $21.9M in Q3 2026 (third quarter 2026), -10% from Q2 2026. Over the last 7 quarters it ranged from $21.9M (Q3 2026) to $27.0M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $21.9M | -10% | -2% |
| Q2 2026 | $24.3M | +3% | -10% |
| Q1 2026 | $23.5M | -5% | -5% |
| Q4 2025 | $24.8M | +10% | — |
| Q3 2025 | $22.5M | -17% | — |
| Q2 2025 | $27.0M | +9% | — |
| Q1 2025 | $24.7M | — | — |
Q3 2026 at a glance
Integra Lifesciences Holdings, Q3 2026: revenue $411M (+2% year over year), operating margin 4.6%, net earnings $14.9M, operating cash flow $96.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Integra Lifesciences Holdings' R&D spending?
Integra Lifesciences Holdings' R&D spending was $21.9M in Q3 2026 (third quarter 2026), -10% from Q2 2026.
How has Integra Lifesciences Holdings' R&D spending changed?
Over the last 7 quarters it ranged from $21.9M (Q3 2026) to $27.0M (Q2 2025).
Q3 2026 results → · How Integra Lifesciences Holdings makes money →